MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2024 International Congress

September 27-October 1, 2024. Philadelphia, PA.

View by Title View Sessions
Jump to:  View All • a b c d e f g h i j k l [m] n o p q r s t u v w x y z
  • Machine Learning Model Comparison for Freezing of Gait Prediction in Advanced Parkinson’s Disease Patients

    J. Watts, A. Khojandi, R. Ramdhani (Knoxville, USA)

  • Machine Learning-Driven Exploration of Epigenetic Patterns in Huntington’s Disease: Understanding Histone Modification Dynamics

    R. Fajar, E. Syfaruddin, S. Putri (Sleman, Indonesia)

  • Magnetic resonance-guided focused ultrasounds (MRgFUS) thalamotomy for disabling tremor secondary to multiple sclerosis.

    A. Menéndez, L. Ispierto, M. Tardaguila, J. Muñoz, C. Ramo-Tello, A. González, R. Alvarez, D. Vilas (Badalona, Spain)

  • Maintaining Isometric Contraction in Parkinson’s Disease: Effect of PD-Medication on EMG Amplitude

    B. Afsharipour, F. Roy, M. Schindle, F. Ba, M. Gorassini, T. Sankar (Edmonton, Canada)

  • Malignant Functional Movement Disorders in Children, Experience from a Tertiary Care Center

    M. Hull, A. Boehnke, S. Rahman, M. Salazar, M. Maldonado-Duran, M. Parnes, J. Jankovic (Houston, USA)

  • Managing Cognitive Decline in Vascular Dementia with Associated Parkinsonism

    J. Hall, R. Islam, C. Rowan, B. Carr (GAINESVILLE, USA)

  • Manganese-induced Parkinsonism Vs Rotenone-induced Parkinsonism: Animal Life Matters!

    S. Chib (Bathinda, India)

  • Mapping Cholinergic Signaling in Parkinson Disease Using [18F]VAT

    J. O'Donnell, M. Campbell, S. Norris, B. Maiti, A. Soda, S. Moerlein, Z. Tu, J. Perlmutter (St. Louis, USA)

  • Mapping the distribution of neurotransmitters to resting-state functional connectivity in patients with Parkinson’s disease

    W. Li, N. Lao-Kaim, R. Li, A. Martín-Bastida, A. Roussakis, G. Searle, N. Valle-Guzman, V. Dayal, D. Athauda, Z. Kefalopoulou, P. Mahlknecht, A. Church, K. Peall, H. Widner, G. Paul, T. Foltynie, R. Barker, P. Piccini (London, United Kingdom)

  • Mapping the Efficacy Landscape: A Network Meta-Analysis of Pharmacological Interventions in Huntington’s Disease

    A. Bhonsale, V. Suresh, B. Javed, M. Shamim, T. Dave, V. Ghosh, S. Sen, M. Muneer, D. Dey, M. Jayan, B. Dhakal, S. Vasipalli, R. Jena (Nagpur, India)

  • Mapping the Landscape of Tourette Syndrome Research: A Bibliometric Analysis

    A. Subhedar, T. Lalotra, S. Khankar, S. Joshi, S. Mast, A. Bhonsale (Nagpur, India)

  • Masticatory function evaluation methods in movement disorders

    Y. Navarrete Cortés, P. Castelo, L. Feitosa, G. Azevedo Diaféria, A. Said, C. Ribeiro Neves, O. Barsottini, S. Bommarito (São Paulo, Brazil)

  • Matrix in the Classroom: Augmented Reality’s Role in the Transformation of Neuroanatomy Education

    J. Brainer, A. Fox, P. Brainer, P. Brainer, A. Brainer (Recife, Brazil)

  • MDS Clinical Supportive Criteria for Parkinson’s Disease are Associated with α-Synuclein Seed Amplification Assay Status

    D. Belete, E. Mitchell, N. Donkor, A. Noyce, C. Simonet (London, United Kingdom)

  • MDS PD e-Diary – a New Patient-Centered Digital Tool for People with Parkinson’s Disease

    P. Rábano-Suárez, MHG. Monje, JA. Vizcarra, SS. Paul, S. Avión, M. Morse, M. Skorvanek, MHS. Tosin, R. Fuller, TH. Turner, M. Dekker, DA. Hall, K. Bergmann, J. Cedarbaum, W. Maetzler, AJ. Espay, P. Martínez-Martín, GT. Stebbins, T. Mestre, A. Sánchez-Ferro (Madrid, Spain)

  • MDSGene Update and Expansion: Clinical and Genetic Spectrum of LRRK2 Variants in Parkinson´s Disease

    C. Krüger, S-Y. Lim, A. Buhrmann, FL. Fahrig, C. Gabbert, N. Bahr, H. Madoev, C. Marras, C. Klein, K. Lohmann (Luebeck, Germany)

  • Measures of Mitochondrial Function in Serum across the Parkinson’s Disease Spectrum

    L. Neilson, J. Elliott, M. Lim, N. Gray (Portland, USA)

  • Measuring Cortisol Levels in Persons with Huntington’s Disease

    A. Clarke, B. Lobb, A. Hiller (Portland, USA)

  • Measuring Motor Improvement with a Wearable Device in a Parkinson Disease Patient undergoing Subcutaneous Levodopa Carbidopa Infusion

    N. Lopez Ariztegui, MI. Morales Casado, G. Tabar Comellas (TOLEDO, Spain)

  • Mechanical and thermal thresholds in the MPTP macaque model of Parkinson’s disease

    A. Sadoun, Q. Li, E. Pioli, T. Dhellemmes, M. Landry, E. Bezard (Floirac, France)

  • Mechanism Study of Familial Cortical Myoclonic Tremor with Epilepsy Type 1 Caused by Pentanucleotide Repeat Expansion in the SAMD12 Gene

    Z-D. Cen, F. Zhang, Y-L. Chen, X-H. Chen, W. Luo (Hangzhou, China)

  • Medication Effects on Bradykinesia and Tremor in Parkinson’s Disease, Measured by Wearable Sensors

    R. Weijer, A. Szanto, V. Exadaktylos, J. van Hilten, D. Hepp (Leiden, Netherlands)

  • Medication Refractory Restless Legs Syndrome: Real-World Experience

    P. Petramfar, J. Jankovic (Houston, USA)

  • Melatonin Modulates NLRP3 Inflammasome Activation through TLR2 to Protect Against Parkinson’s Disease

    XY. Wang, JW. Li, HS. Liu, XN. Xiong (Wuhan, China)

  • Meta-Analysis of Two Randomized Controlled Trials Assessing the Efficacy of Mesdopetam (IRL790) in Levodopa-Induced Dyskinesia in Parkinson’s Disease

    F. Hansson, S. Waters, N. Waters, J. Tedroff (Gothenburg, Sweden)

  • Metabolic characteristics of brain network in patients with Parkinson’s disease after Deep brain stimulation

    WEI. Lin, LJJ. Jin, KLY. Yang, HYW. Wang (WUXI CITY, China)

  • Metabolic Covariance Networks in Progressive Supranuclear Palsy Revealed by Spatial independent component analysis

    B. Wang, H. Wang, W. Luo (Hangzhou, China)

  • Metabolic Progressive Subtypes in Progressive Supranuclear Palsy

    H. Wang (Hangzhou, China)

  • Metabolic Regulators of Mitochondrial DNA Release in Cellular Models of PRKN-linked Parkinson’s Disease

    G. Agyeah, J. Ghelfi, L. Gallucci, A. Rakovic, P. Antony, S. Pereira, A. Grünewald (Belval Esch-sur-Alzette, Luxembourg)

  • MIBG Uptake in the Major Salivary Glands in Patients with Parkinson’s Disease and Dementia with Lewy Bodies

    J. Ebina, S. Mizumura, H. Morioka, M. Shibukawa, J. Nagasawa, M. Yanagihashi, T. Hirayama, N. Ishii, Y. Kobayashi, A. Inaba, S. Orimo, O. Kano (Tokyo, Japan)

  • Microstructural Changes in the Inferior Tuberal Hypothalamus Correlate with Daytime Sleepiness in Lewy Body Disease

    J. Cohen, H. Radhakrishnan, C. Olm, S. Das, P. Cook, D. Wolk, D. Weintraub, D. Irwin, C. Mcmillan (Philadelphia, USA)

  • Mild Behavioral Impairment in Lewy body disease: a potential marker of phenoconversion and disease severity

    B. Jin, E. Yoon, S. Kim, S. Lee, H. Nam, Y. Kim, B. Jeon, J. Lee (Seoul, Republic of Korea)

  • Minimally Clinical Important Differences of Hemifacial Spasm Score-30 (HFS-30) and Hemifacial Spasm Score-7 (HFS-7) for Patients with Hemifacial spasm

    N. Inthapong, W. Saengphatrachai, Y. Pitakpatapee, N. Rattanathamsakul, P. Sirvanitchapoom (Bangkok, Thailand)

  • Miniscope-based neural circuit profiling in freely behaving animals for preclinical therapeutic assessment

    S. Huang, D. Cheng, A. Simmonet, E. Noe, E. Bezard, J. Zapata, J. Nassi (Mountain View, USA)

  • Misdiagnosing Movement Disorders on a Terciary Academic Center in the Caribbean: A Series of Cases

    S. Castro, C. Torres, W. Castro, J. Carbonell, I. Zabala, A. de Peña, V. Espaillat, D. Santos, P. Roa, F. Taveras, Y. Suero (Distrito Nacional, Dominican Republic)

  • Misdiagnosis of Cognitive Impairment in Parkinson’s disease

    F. Rodriguez-Porcel, T. Turner (Charleston, USA)

  • Misinterpretation of Hypnagogic/hypnopompic Experiences as Hallucinations in Parkinson’s Disease

    D. Urso, V. Gnoni, A. Giugno, M. Caccamo, A. Nanni, G. Logroscino, G. Foffani (Tricase, Italy)

  • Mitigating The Impact Of Covid-19 On Parkinson’s Disease: Insights From Vaccination Strategies

    J. Salimjonov, KH. Khalimova, N. Rashidova, R. Matmurodov (Tashkent, Uzbekistan)

  • Mitochondrial Complex I Brain Imaging in Parkinson’s Disease and Lewy Body Dementia

    S. Berman, J. Stehouwer, C. Mathis, W. Klunk, H. Tsukada, S. Royse, A. Reese, T. Overbey, J. Greenamyre, G. Sjobeck, D. Tudorascu, B. Lopresti (Pittsburgh, USA)

  • Mixed Brain Pathology in Neurodegenerative Parkinsonism and Dementia

    K. Mensikova, L. Tuckova, D. Hrabos, A. Jawad, P. Kanovsky (Olomouc, Czech Republic)

  • Mixed Cerebellar Ataxia in a Patient with a Novel FAT2 Gene Variant Associated with SCA45

    A. Richmond, M. Nashatizadeh, R. Townley (Columbia, USA)

  • Model-Based Gait Outcomes to Track Parkinson’s Disease Progression ?

    CE. Mvomo, J. Bedime, S. Perfetto, I. Sierra, H. Lajeunesse, A. Potvin-Desrochers, CA. Easthope, C. Paquette (Montreal, Canada)

  • Modeling the Role of Parkinson’s Disease-Specific Factors in Depression and Anxiety: Findings from MEX-PD Cohort

    P. Reyes-Pérez, D. Martínez, I. Estrada-Bellmann, C. Guerra-Galicia, N. Gandarilla-Martínez, E. Morelos Figaredo, K. Salinas-Barboza, Y. Matuk-Pérez, A. Lazaro-Figueroa, M. Rentería, S. Alcauter-Solorzano, A. Ruiz-Contreras, A. Medina-Rivera (Queretaro, Mexico)

  • Moderate-to-severe upper limb spasticity patterns in the elderly are improved following treatment with incobotulinumtoxinA: a pooled analysis

    M. Munin, A. Camões-Barbosa, C. Cordero-García, M. Althaus, G. Comes, M. Vacchelli, C. Walter, J. Wissel (Pittsburgh, USA)

  • Moderators of aerobic exercise effects on motor symptoms in patients with Parkinson’s disease: a systematic review and meta-analysis

    R. Kim, N. Kang (Seoul, Republic of Korea)

  • Modifiable factors associated with Huntington’s disease progression in presymptomatic participants: explained longitudinal machine learning modelling

    A. Gil-Salcedo, R. Massart, L. Cleret-de-Langavant, A. Bachoud-Levi (Paris, France)

  • Molecular Landscape of Gastrointestinal Dysfunctions in Parkinson’s Disease

    M. Lai, S. Kulkarni, B. Benitez (Boston, USA)

  • Monitoring Progress: Use of the Behavioral Dyscontrol Scale-2 (BDS-2) in FXTAS (Fragile X-associated Tremor Ataxia Syndrome) Progression

    H. Hasan, A. Mokhtabad Amrei, E. Santos, H. Biag, A. Schneider, J. Wang, R. Hagerman (Sacramento, USA)

  • Monopolar sensing improves the efficiency of DBS programming in Parkinson’s disease

    J. Thompson, E. Radcliffe, S. Ojemann, D. Kramer, A. Baumgartner, D. Kern, M. Case, C. Zarns, A. Holt-Becker, R. Raike (Aurora, USA)

  • Mood and Apathy Outcomes after STN or GPi DBS for Parkinson’s Disease: An Interim Report from the ADROIT NAPA Sub-study

    S. Groppa, M. Figee, I. Muro Garcia, A. Schnitzler, S. Chen, L. Himes, M. Frassica, D. Nanduri, A. Gharabaghi (Mainz, Germany)

  • Morphology and Functional Connectivity of the Basolateral Amygdala and Rapid Eye Movement Sleep Behavior Disorder

    Z. Song, Z. Wang, B. Zhang, J. Pu (Hangzhou, China)

  • Mortality Rate, Cause of Death and Factors Associated with Mortality in Late Stage Parkinson’s Disease

    K. Rosqvist, P. Odin (Lund, Sweden)

  • Motion-robust high-resolution imaging of nigrosome-1 in Parkinson’s disease

    M. Skorpil, O. Norbeck, P. Svenningsson, S. Skare, A. van Niekerk (Stockholm, Sweden)

  • Motor and Non-Motor Characteristics of Parkinson’s Disease in a Prevalent Population in Tanzania

    R. Morton, O. Williams, J. Josephat, M. Dekker, W. Howlett, E. Assey, N. Fothergill-Misbah, C. Dotchin, S. Urasa, R. Walker (North Shields, United Kingdom)

  • Motor and Non-Motor Outcomes of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study

    C. Henchcliffe, H. Sarva, A. Lozano, A. Fasano, S. Kalia, K. Yu, C. Brennan, W. Stemple, N. Abid, M. Yountz, A. Enayetallah, A. Lampron, V. Tabar (Orange, USA)

  • Motor and Quality of Life Outcomes of Deep Brain Stimulation for Pediatric Dystonia – CHILD-DBS Registry

    W K. Lim, C. Gorodetsky, G. Ibrahim, K. Mithani, S. Breitbart, A. Leblanc-Millar, A. Fasano (Toronto, Canada)

  • Motor Impact of Fasting in Parkinson’s Disease Patients: An overview

    N. Kouki, M. Messelmani, N. Kouki, H. Derbali, J. Zaouali, R. Mrissa (tunis, Tunisia)

  • Motor Onset of Parkinson’s disease: the proximal limbs are first

    MA. Ruiz Yanzi, M. Matarazzo, T. Jiménez-Castellanos, JA. Pineda-Pardo, MHG. Monje, A. Sánchez-Ferro, C. Gasca-Salas, R. Martínez-Fernández, JA. Obeso (Madrid, Spain)

  • Motor Phenotype Changes over time in Parkinson’s Disease. A 5-year Follow-up Study

    MF. Valero García, E. Bargay Pizarro, I. Legarda Ramirez, B. Vives Pastor, L. Núñez Santos, S. Jesus Maestre, M. Cosgaya, J. Garcia Caldentey, N. Caballol, J. Hernández Vara, I. Cabo, L. López Manzanares, I. González Aramburu, C. Borrué, B. Solano Vila, M. álvarez Saúco, L. Vela, S. Escalante, E. Cubo, JC. Martínez Castrillo, P. Sánchez Alonso, MG. Alonso Losada, N. López Ariztegui, I. Gastón, J. Kulisevsky, M. Seijo Martinez, C. Ordás, P. Martinez-Martin, P. Mir, D. Santos-García (Palma de Mallorca, Spain)

  • MOVE-PD: Mapping the Correlation of Sedentary behavior with Motor Symptoms in Parkinson’s Disease

    J. Frederiksen, TH. Thomsen, B. Biering- Sørensen, U. Dalgas, M. Langeskov-Christensen (Glostrup, Denmark)

  • Movement Disorder Presentations in Leukoenephalopathy with Calcifications and Cysts

    L. Tochen, J. Harmon, J. Rhee, J. Fraser (Washington, USA)

  • Movement Disorder Society Unified Parkinson’s Disease Rating Scale Motor Examination Retains Its 2-Domain Profile in Both On and Off States

    T. Mestre, G. Stebbins, C. Goetz, S. Luo (Ottawa, Canada)

  • Movement Disorders Associated with Infectious Encephalitis in Pediatric Patients

    M. Mnif, H. Benrhouma, T. Benyounes, H. Klaa, Z. Miladi, A. Zioudi, I. Turki, I. Kraoua (Tunis, Tunisia)

  • Movement Disorders in Anti-IGLON5 Antibody Disease

    S. Garg, J. Kaur, K. Karan, D. Nanduri (Bengaluru, India)

  • Movement Disorders in Autoimmune Encephalitis: A case series of 11 cases.

    G. Costa, C. Del Prado, A. Marin, I. Apaza, M. Bendersky, C. Simison, P. Hernandez, F. Echeverria, T. Arakaki, S. Rodriguez Quiroga, N. Garretto (CABA Buenos Aires, Argentina)

  • Movement disorders in Brain Sagging Syndrome- A Systematic Review

    A. Datta, A. Lenka (Minneapolis, USA)

  • Movement Disorders in Cerebrotendinous Xanthomatosis

    M. Alquaimi, M. Almugbil, R. Sulaiman, Z. Alhassnan, S. Bohlega (Riyadh, Saudi Arabia)

  • Movement Disorders In Children With Monoamine Neurotransmitter Disorders

    M. Ben Hafsa, H. Benrhouma, T. Ben Younes, H. Klaa, A. Zioudi, Z. Miladi, I. Ben Youssef-Turki, I. Kraoua (Tunis, Tunisia)

  • Movement Disorders in De Novo Hyperglycemic Crisis: Insights from a Clinical Case Series

    D. Japón-Cueva, C. Rodriguez-Alarcon, A. Carofilis-Cornejo, L. Viñan-Paucar, M. Cueva-Espinoza, P. Gruezo-Realpe, D. Ocampo, R. Santibanez-Vasquez (Guayaquil, Ecuador)

  • Movement disorders in patients with central nervous system tuberculosis: A systematic review

    K. Acurio Ortiz, N. Pacheco-Barrios, A. Flores-Gavino, F. Váscones-Román, I. Calisaya-Madariaga, M. Guerrero-Yrene, W. Rios-Garcia, L. Quintana- Garcia, E. Urrea-Mendoza (Lima, Peru)

  • Movement Disorders in the Emergency:New Insights

    A. Banik, D. Manna, S. Pal, A. Chakravarty, I. Dutta, A. Chattopadhyay, S. Banerjee (kolkata, India)

  • Movement Disorders Knowledge Among Medical Professionals in Central Asia

    ZH. Myrzayev, J. Sringean, R. Bhidayasiri (Almaty, Kazakhstan)

  • Movement disorders secondary to neurocysticercosis: a case report from Bolivia

    M. Jauregui, S. Silva, P. Chana-Cuevas, P. Salles (La Paz, Bolivia)

  • Movement-Related Potentials Recorded Using Cerebellar Deep Brain Stimulation Leads

    U. Saha, T. Grippe, Y. Lin, M. Callister, G. Sorrento, J. Nankoo, R. Munhoz, A. Fasano, S. Kalia, R. Chen (Toronto, Canada)

  • MR-guided focused ultrasound for essential tremor: exploratory analysis comparing unilateral and staged, bilateral thalamotomy

    HM. Eisenberg, P. Fishman, P. Ghanouni, M. Grassman, C. Ferrer, K. Gant, A. Grinspan (Baltimore, USA)

  • MRgFUS thalamotomy for essential tremor: Lesion location and clinical outcomes

    M. Rodriguez-Oroz, AA. Arcadi, LGQ. Gonzalez Quarante, IA. Aviles-Olmos, AMB. Bastidas, AJH. Jimenez Huete, AG. Gorospe, JG. Guridi (Pamplona, Spain)

  • MRgFUS thalamotomy for tremor-predominant Parkinson´s disease: a single-center prospective study

    C. Ochoa-Lopez, A. Martín-Bastida, B. Garate-Andikoetxea, C. Sanchez-Catasus, A. Gorospe-Osinalde, A. Jiménez-Huete, I. Avilés-Olmos, A. Arcadi, LH. González-Quarante, J. Guridi, MC. Rodríguez-Oroz (Pamplona, Spain)

  • MRI Predictive Marker of the Vestibular Galvanic Stimulation Effectiveness in the Postural Instability Treatment in Parkinson’s Disease.

    O. Alenikova, A. Chumak A, G. Zobnina, D. Antonenka (Minsk, Belarus)

  • MRI Visible Perivascular Spaces are Associated with Disease Duration and Severity in Parkinson’s Disease

    D. Hemachandra, K. Younes, E. Peterson, J. Winer, Y. Cobbigo, H. Rosen, C. Young, T. Schulte, K. Poston, E. Müller-Oehring (Palo Alto, USA)

  • Multicenter study of efficacy and safety of subcutaneous foslevodopa/foscarbidopa treatment initiation or switch from LD/CD intestinal gel

    M. Morales-Casado, G. Tabar-Comellas, E. Gisbert-Tijeras, DD. García-Meléndez, J. Domínguez-Bértalo, D. Rivero-Rodríguez, N. López-Ariztegui (Toledo, Spain)

  • Multicentric Randomized Control Trial of Buspirone in Levodopa-Induced Dyskinesias

    H. Salhi, D. Maltête, S. Thobois, G. Fenelon, F. Ory, L. Defevre, G. Mangone, G. Defer, AR. Marques, S. Frismand, S. Drapier, JP. Azulay, C. Geny, G. Dupont, A. Doe-de-Maindreville, C. Barberot, D. Devos, JC. Corvol, O. Rascol, E. Audureau, P. Remy (Creteil, France)

  • Multifaceted Challenges in Multisystem Atrophy Management: Medication Sensitivity, Emotional Lability, and Increased Fall Risk

    G. Legerme, B. Carr, C. Rowan (Gainesville, USA)

  • Multiple System Atrophy in a Patient with Normal Pressure Hydrocephalus

    E. Hayden, M. Elkasaby, B. Appleby (Cleveland, USA)

  • Muscle Augmentation Paradox: Contrasting Therapeutic Approaches in Myasthenia Gravis and Parkinson’s Disease

    G. Legerme, D. Nolasco, A. Sohel, A. Wu, B. Carr (Gainesville, USA)

  • Muscle co-contraction in people with Parkinson’s disease suffering from freezing of gait

    D. Buzaglo, P. Gandhi, Y. Hanein, J. Hausdorff (Tel Aviv, Israel)

  • Muscle mass, body fat mass, and nutrition in patients with Huntington´s Disease

    M. Peball, P. Schörghuber, F. Carbone, P. Mahlknecht, F. Krismer, A. Djamshidian, K. Schwarzova, K. Seppi, B. Heim (Innsbruck, Austria)

  • Muscle selection and dosing in patients undergoing treatment with abobotulinumtoxinA for lower limb spasticity in real world practice

    R. Zorowitz, J. Jacinto, S. Ashford, M. Beneteau, P. Maisonobe, C. Hannes, A. Esquenazi (Washington, USA)

  • Mutation of the ATP5F1A gene associated with dystonia, spasticity, myoclonus, cognitive impairment and epilepsy – a rare case report of a patient

    M. Danis, G. Krastev, J. Necpal, R. Jech, M. Zech (Trnava, Slovakia)

  • Myoclonus and Encephalitis as an Adverse Event of mRNA COVID-19 Vaccine

    A. Kim, N. Kim, Y. Ju, Y. Jeon, SJ. Park (Cheongju, Republic of Korea)

Jump to:  View All • a b c d e f g h i j k l [m] n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley